Sector News

Haemonetics Expands Executive Management Roles To Complement Global Growth Strategy

April 28, 2015
Life sciences
/PRNewswire/ – Haemonetics Corporation announced today expanded roles for two executives.  These changes are part of an ongoing plan to advance the Company’s global leadership in blood management solutions and to execute on strategies to enhance shareholder value.
 
Kent Davies, who joined the Company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO.  In this expanded role, Mr. Davies will have overall accountability for the Company’s commercial, product development and product management focus across the entire portfolio and in all geographies. 
 
Byron Selman, who joined the Company upon the acquisition of Pall Corporation’s transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies.  Mr. Selman will oversee the Company’s global commercial and market development efforts, with the exception of the Company’s commercial Plasma business. 
 
Mr. Concannon stated: “Haemonetics enters fiscal 2016 with good momentum, brought about by recent contract wins, new product innovations and launches, and a Comprehensive Blood Management Solutions (CBMS) offering that is gaining traction with customers.  These two management promotions will enhance our execution efforts and strategic focus in all of our markets, while leveraging our strengths in product management and product development.”
 
Source: Haemonetics

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach